Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast.

Similar presentations


Presentation on theme: "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast."— Presentation transcript:

1 Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial Dr Helena M Earl, MBBS, Louise Hiller, PhD, Prof Janet A Dunn, PhD, Clare Blenkinsop, Louise Grybowicz, BSc, Anne-Laure Vallier, MSc, Jean Abraham, MBBS, Jeremy Thomas, MBBS, Elena Provenzano, MD, Luke Hughes-Davies, MBBCh, Ioannis Gounaris, MD, Karen McAdam, MBBS, Stephen Chan, MBBCh, Rizvana Ahmad, MBBS, Tamas Hickish, MBBS, Stephen Houston, MBBS, Daniel Rea, PhD, Prof John Bartlett, PhD, Prof Carlos Caldas, MD, Prof David A Cameron, MD, Larry Hayward, MBChB The Lancet Oncology Volume 16, Issue 6, Pages 656-666 (June 2015) DOI: 10.1016/S1470-2045(15)70137-3 Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions

2 Figure 1 The Lancet Oncology 2015 16, 656-666DOI: (10.1016/S1470-2045(15)70137-3) Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions

3 Figure 2 The Lancet Oncology 2015 16, 656-666DOI: (10.1016/S1470-2045(15)70137-3) Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions


Download ppt "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast."

Similar presentations


Ads by Google